Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat
- PMID: 20682600
- DOI: 10.1258/ebm.2010.010082
Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat
Abstract
Alimentary tract (AT) mucositis is a serious and debilitating side-effect of cancer therapy primarily characterized by damage of the mucous membranes throughout the AT. It is well established that this damage is a result of up-regulation of stress response genes and pro-inflammatory cytokines. Matrix metalloproteinases (MMPs) have been shown to function in several of the pathways known to be up-regulated in mucositis and play a key role in tissue injury and inflammation in many gastrointestinal disorders. This study aims to characterize the expression of multiple MMPs including MMP-1, -2, -3, -9 and -12 and their inhibitors, tissue inhibitor of metalloproteinase (TIMP)-1 and -2, in a rat model of irinotecan-induced mucositis. Dark agouti rats were administered a single 200 mg/kg intraperitoneal dose of irinotecan and killed at 1, 6, 24, 48, 72, 96 and 144 h following treatment. Hematoxylin and eosin staining, immunohistochemistry and realtime polymerase chain reaction were used to assess histopathological damage and MMP expression in the jejunum and colon. Marked histopathological evidence of mucositis was observed in the jejunum and colon as early as six hours following irinotecan treatment. A significant alteration in both gene expression and tissue levels of MMPs and TIMPs was noted following irinotecan. The increase in MMP-2, -3, -9 and -12 levels was associated with inflammatory infiltrate and maximum tissue damage. In contrast, MMP-1 expression correlated with tissue restitution. TIMP-1 and -2 levels were significantly altered in the jejunum following irinotecan. The augmentation in the expression profiles of MMPs and their inhibitors correlated with histopathological alterations observed in the tissue following irinotecan. This prompts the consideration of MMPs as possible mediators of chemotherapy-induced mucositis.
Similar articles
-
Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.Cancer Chemother Pharmacol. 2008 Jun;62(1):33-41. doi: 10.1007/s00280-007-0570-0. Epub 2007 Aug 17. Cancer Chemother Pharmacol. 2008. PMID: 17703303
-
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?Cancer Chemother Pharmacol. 2009 Jan;63(2):239-51. doi: 10.1007/s00280-008-0732-8. Epub 2008 Mar 20. Cancer Chemother Pharmacol. 2009. PMID: 18351341
-
Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study.Support Care Cancer. 2017 Feb;25(2):391-398. doi: 10.1007/s00520-016-3413-x. Epub 2016 Sep 20. Support Care Cancer. 2017. PMID: 27650103
-
Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?Cancer Chemother Pharmacol. 2009 Jun;64(1):1-9. doi: 10.1007/s00280-009-0984-y. Epub 2009 Mar 21. Cancer Chemother Pharmacol. 2009. PMID: 19305997 Review.
-
Matrix metalloproteinases and gut toxicity following cytotoxic cancer therapy.Curr Opin Support Palliat Care. 2014 Jun;8(2):164-9. doi: 10.1097/SPC.0000000000000049. Curr Opin Support Palliat Care. 2014. PMID: 24752198 Review.
Cited by
-
Emerging evidence on the pathobiology of mucositis.Support Care Cancer. 2013 Nov;21(11):3233-41. doi: 10.1007/s00520-013-1900-x. Epub 2013 Jul 11. Support Care Cancer. 2013. PMID: 23842598 Review.
-
Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model.Chemotherapy. 2018;63(5):284-292. doi: 10.1159/000495470. Epub 2019 Feb 7. Chemotherapy. 2018. PMID: 30731451 Free PMC article. Clinical Trial.
-
Intestinal Adaptation upon Chemotherapy-Induced Intestinal Injury in Mice Depends on GLP-2 Receptor Activation.Biomedicines. 2021 Jan 7;9(1):46. doi: 10.3390/biomedicines9010046. Biomedicines. 2021. PMID: 33430185 Free PMC article.
-
Emerging evidence on the pathobiology of mucositis.Support Care Cancer. 2013 Jul;21(7):2075-83. doi: 10.1007/s00520-013-1810-y. Epub 2013 Apr 21. Support Care Cancer. 2013. PMID: 23604521 Review.
-
Periodontal Disease - A Late Complication of Head and Neck Cancer Radiotherapy.Cancer Control. 2024 Jan-Dec;31:10732748241255845. doi: 10.1177/10732748241255845. Cancer Control. 2024. PMID: 38760005 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous